fda halts glp-1 US signals crackdown on compounded weight-loss drugs; Hims shares tumble FDA Ban on Compounded GLP-1

Proper dosing ensures adequate tissue concentrations throughout your target window

GLP-1 receptor agonists are a class of medications primarily licensed for the treatment of type 2 diabetes mellitus and, in some formulations, for weight management in adults with obesity or overweight with weight-related comorbidities

Lillig et al., 2008

The only quirk: no branding on the packaging, which made it a little awkward to confirm where the medication came from

Dangers to American patients Counterfeit GLP-1s Ozempic and Mounjaro fakes have appeared in dozens of countries, including Mexico, Canada, and the U.S

The evidence base is overwhelmingly preclinical, and there are no completed, published Phase 2 or 3 human efficacy trials only early-stage safety work [9]